Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tissue Transplantation01:24

Tissue Transplantation

1.4K
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
1.4K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.9K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.9K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

64.0K
Overview
64.0K
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

815
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
815

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HLA matching in contemporary haematopoietic cell transplantation: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Bone marrow transplantation·2026
Same author

Nomenclature for Factors of the HLA System, 2026.

HLA·2026
Same author

Quantile regression of the relationship between demographic factors and leukocyte telomere length, measured by Southern blot and qPCR.

GeroScience·2026
Same author

Novel Genomic Biomarkers Improve Post-Hematopoietic Cell Transplantation Relapse Risk Stratification for Patients With Myelodysplastic Syndromes.

JCO precision oncology·2026
Same author

Autoimmune HLA alleles and neoantigens predict myelodysplastic syndrome outcomes after allogeneic HSCT: A CIBMTR analysis.

iScience·2026
Same author

Validated clinical risk score for acute graft-versus-host disease in adult allogeneic hematopoietic cell transplantation.

Blood advances·2026
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Related Experiment Video

Updated: Apr 24, 2026

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
08:07

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation

Published on: September 6, 2017

9.8K

Extended HLA Haplotypes and Transplant Survival.

Effie W Petersdorf1, Caroline McKallor2, Mari Malkki1

  • 1Fred Hutchinson Cancer Center, Seattle, Washington, United States.

Blood
|April 22, 2026
PubMed
Summary
This summary is machine-generated.

Extended human leukocyte antigen (HLA) haplotypes including class III variation improve hematopoietic-cell transplantation outcomes. Identifying favorable patient and donor markers, like SNP rs915654, reduces mortality and relapse risks.

More Related Videos

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

14.9K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

13.8K

Related Experiment Videos

Last Updated: Apr 24, 2026

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
08:07

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation

Published on: September 6, 2017

9.8K
Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

14.9K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

13.8K

Area of Science:

  • Immunogenetics
  • Transplantation immunology
  • Genomic medicine

Background:

  • The role of extended human leukocyte antigen (HLA) class I, III, and II haplotypes in hematopoietic-cell transplantation (HCT) success is not fully understood.
  • Functional variation within the HLA class III region is crucial but often overlooked in HCT donor selection.

Purpose of the Study:

  • To investigate the impact of extended HLA haplotypes, including class III single-nucleotide polymorphisms (SNPs), on HCT outcomes.
  • To identify specific HLA class III SNPs that predict mortality and relapse after HCT.

Main Methods:

  • Multivariable regression analysis of 26 candidate class III SNPs in 1,436 patients and their haploidentical related donors.
  • Haplotype analysis incorporating class I, class II loci, and the identified class III SNP (rs915654).
  • Validation in an independent cohort of 1,141 haploidentical transplants.

Main Results:

  • A specific class III SNP, rs915654, was significantly associated with reduced mortality and relapse.
  • Incorporating rs915654 into existing HLA models improved their predictive power for relapse and mortality.
  • The number of favorable patient and donor markers correlated inversely with mortality and relapse risks, including non-relapse mortality.

Conclusions:

  • Extended HLA class I-III-II haplotypes significantly influence HCT success.
  • The identified class III SNP (rs915654) provides valuable prognostic information.
  • Optimizing haploidentical donor selection using comprehensive HLA haplotype data can improve transplant outcomes.